AlphaQuest LLC Purchases 2,588 Shares of KalVista Pharmaceuticals, Inc. (NASDAQ:KALV)

AlphaQuest LLC grew its position in KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) by 17.1% during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 17,700 shares of the specialty pharmaceutical company’s stock after purchasing an additional 2,588 shares during the quarter. AlphaQuest LLC’s holdings in KalVista Pharmaceuticals were worth $150,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also modified their holdings of the stock. China Universal Asset Management Co. Ltd. grew its stake in shares of KalVista Pharmaceuticals by 24.7% in the fourth quarter. China Universal Asset Management Co. Ltd. now owns 10,329 shares of the specialty pharmaceutical company’s stock worth $87,000 after acquiring an additional 2,043 shares during the last quarter. SG Americas Securities LLC grew its stake in shares of KalVista Pharmaceuticals by 10.0% in the fourth quarter. SG Americas Securities LLC now owns 14,508 shares of the specialty pharmaceutical company’s stock worth $123,000 after acquiring an additional 1,319 shares during the last quarter. Hennion & Walsh Asset Management Inc. acquired a new stake in shares of KalVista Pharmaceuticals in the fourth quarter worth $634,000. JPMorgan Chase & Co. grew its stake in shares of KalVista Pharmaceuticals by 8.0% in the third quarter. JPMorgan Chase & Co. now owns 22,610 shares of the specialty pharmaceutical company’s stock worth $262,000 after acquiring an additional 1,670 shares during the last quarter. Finally, Barclays PLC grew its stake in shares of KalVista Pharmaceuticals by 418.5% in the third quarter. Barclays PLC now owns 67,222 shares of the specialty pharmaceutical company’s stock worth $778,000 after acquiring an additional 54,257 shares during the last quarter.

KalVista Pharmaceuticals Stock Performance

Shares of NASDAQ:KALV opened at $12.49 on Tuesday. KalVista Pharmaceuticals, Inc. has a 52 week low of $7.30 and a 52 week high of $15.50. The company’s fifty day moving average is $9.82 and its 200-day moving average is $10.26. The company has a market capitalization of $617.23 million, a PE ratio of -3.43 and a beta of 0.76.

Insider Activity

In other news, major shareholder Venrock Healthcare Capital Par bought 43,707 shares of KalVista Pharmaceuticals stock in a transaction dated Thursday, January 30th. The shares were bought at an average price of $8.76 per share, for a total transaction of $382,873.32. Following the purchase, the insider now owns 4,986,480 shares of the company’s stock, valued at approximately $43,681,564.80. This trade represents a 0.88 % increase in their ownership of the stock. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, insider Paul K. Audhya sold 3,125 shares of the business’s stock in a transaction on Tuesday, February 18th. The shares were sold at an average price of $9.82, for a total transaction of $30,687.50. Following the completion of the sale, the insider now owns 100,334 shares in the company, valued at $985,279.88. This represents a 3.02 % decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders have bought 236,055 shares of company stock worth $2,162,146 and have sold 17,292 shares worth $184,625. 10.50% of the stock is owned by corporate insiders.

Wall Street Analyst Weigh In

Several equities research analysts have recently issued reports on the stock. Cantor Fitzgerald restated an “overweight” rating on shares of KalVista Pharmaceuticals in a research note on Monday, December 9th. Bank of America started coverage on shares of KalVista Pharmaceuticals in a research note on Wednesday, December 18th. They set a “buy” rating and a $22.00 price target on the stock. JMP Securities started coverage on shares of KalVista Pharmaceuticals in a research note on Friday, January 31st. They set an “outperform” rating and a $19.00 price target on the stock. Needham & Company LLC reiterated a “buy” rating and set a $28.00 price target on shares of KalVista Pharmaceuticals in a research note on Thursday, March 13th. Finally, HC Wainwright reiterated a “buy” rating and set a $20.00 price target on shares of KalVista Pharmaceuticals in a research note on Friday. Six equities research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat, the stock has an average rating of “Buy” and a consensus target price of $23.80.

KalVista Pharmaceuticals Company Profile

KalVista Pharmaceuticals, Inc, a clinical stage pharmaceutical company, engages in the discovery, development, and commercialization of drug therapies inhibitors for diseases with unmet needs. The company’s product candidate is Sebetralstat, a small molecule plasma kallikrein inhibitor targeting the disease of hereditary angioedema (HAE).